Posted by Michael Wonder on 26 Oct 2022
PHARMAC funds ramipril for people with high blood pressure
26 October 2022 - PHARMAC today has announced the decision to fund ramipril (branded as Tryzan), an angiotensin-converting enzyme (ACE) inhibitor used to treat a variety of cardiovascular conditions.
The medicine will be funded without restriction and prescribed for any relevant use from 1 December 2022.
